LAVA Therapeutics NV
LVTXHealthcare · Pharmaceutical Preparations · P7 · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY24 | FY23 | |
|---|---|---|
| Revenue | $12.0M | $6.8M |
| Operating income | −$29.7M | −$43.4M |
| Net income | −$25.1M | −$41.9M |
| Total assets | $80.8M | $101.7M |
| Total liabilities | $53.1M | $50.3M |
| Equity | $27.7M | $51.4M |
| EPS (diluted) | $-0.94 | $-1.57 |
| Shares out. | 26.3M | 26.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- −247.8%
- Net margin
- −209.6%
- Return on equity
- −90.5%
- Return on assets
- −31.1%
- Return on capital (ROCE)
- −47.3%
- Liabilities / assets
- 65.7%
- Debt / equity
- 1.91×
- Book value / share
- $1.05
- Revenue growth (YoY)
- 77.0%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- -4.00distress
- Accruals / assets
- −6.9%clean
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 3 warning● 2 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| Nov 14, 2025 | 373,800 | 3.9 | -12.2% |
| Oct 31, 2025 | 425,851 | 1.0 | +136.8% |
| Oct 15, 2025 | 179,838 | 1.1 | +54.3% |
| Sep 30, 2025 | 116,555 | 1.0 | +18.1% |
| Sep 15, 2025 | 98,649 | 1.7 | +11.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Director / officer changeNov 21, 2025
- Delisting / listing-standard notice · Change in control · Director / officer changeNov 13, 2025
- Shareholder voteNov 7, 2025
- Entered a material agreement · Other material eventOct 17, 2025
- Other material eventOct 2, 2025
- Other material eventSep 30, 2025
- Regulation FD disclosure · Other material eventAug 14, 2025
- Entered a material agreement · Regulation FD disclosure · Other material eventAug 4, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.